320 related articles for article (PubMed ID: 36231075)
1. The Tryptophan Catabolite or Kynurenine Pathway in a Major Depressive Episode with Melancholia, Psychotic Features and Suicidal Behaviors: A Systematic Review and Meta-Analysis.
Almulla AF; Thipakorn Y; Vasupanrajit A; Tunvirachaisakul C; Oxenkrug G; Al-Hakeim HK; Maes M
Cells; 2022 Oct; 11(19):. PubMed ID: 36231075
[TBL] [Abstract][Full Text] [Related]
2. The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: A systematic review and meta-analysis.
Almulla AF; Thipakorn Y; Vasupanrajit A; Abo Algon AA; Tunvirachaisakul C; Hashim Aljanabi AA; Oxenkrug G; Al-Hakeim HK; Maes M
Brain Behav Immun Health; 2022 Dec; 26():100537. PubMed ID: 36339964
[TBL] [Abstract][Full Text] [Related]
3. The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: a systematic review and meta-analysis.
Almulla AF; Supasitthumrong T; Tunvirachaisakul C; Algon AAA; Al-Hakeim HK; Maes M
BMC Infect Dis; 2022 Jul; 22(1):615. PubMed ID: 35840908
[TBL] [Abstract][Full Text] [Related]
4. The tryptophan catabolite or kynurenine pathway in autism spectrum disorder; a systematic review and meta-analysis.
Almulla AF; Thipakorn Y; Tunvirachaisakul C; Maes M
Autism Res; 2023 Dec; 16(12):2302-2315. PubMed ID: 37909397
[TBL] [Abstract][Full Text] [Related]
5. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.
Almulla AF; Vasupanrajit A; Tunvirachaisakul C; Al-Hakeim HK; Solmi M; Verkerk R; Maes M
Mol Psychiatry; 2022 Sep; 27(9):3679-3691. PubMed ID: 35422466
[TBL] [Abstract][Full Text] [Related]
6. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
7. The Tryptophan Catabolite or Kynurenine Pathway in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Almulla AF; Supasitthumrong T; Amrapala A; Tunvirachaisakul C; Jaleel AKA; Oxenkrug G; Al-Hakeim HK; Maes M
J Alzheimers Dis; 2022; 88(4):1325-1339. PubMed ID: 35786655
[TBL] [Abstract][Full Text] [Related]
8. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression.
Maes M; Leonard BE; Myint AM; Kubera M; Verkerk R
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):702-21. PubMed ID: 21185346
[TBL] [Abstract][Full Text] [Related]
9. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
10. Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis.
Hebbrecht K; Skorobogatov K; Giltay EJ; Coppens V; De Picker L; Morrens M
Front Immunol; 2021; 12():667179. PubMed ID: 34093561
[TBL] [Abstract][Full Text] [Related]
11. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?
Quak J; Doornbos B; Roest AM; Duivis HE; Vogelzangs N; Nolen WA; Penninx BW; Kema IP; de Jonge P
Psychoneuroendocrinology; 2014 Jul; 45():202-10. PubMed ID: 24845191
[TBL] [Abstract][Full Text] [Related]
12. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies.
Inam ME; Fernandes BS; Salagre E; Grande I; Vieta E; Quevedo J; Zhao Z
Braz J Psychiatry; 2023 May; 45(4):343-55. PubMed ID: 37127280
[TBL] [Abstract][Full Text] [Related]
13. The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation.
Milaneschi Y; Allers KA; Beekman ATF; Giltay EJ; Keller S; Schoevers RA; Süssmuth SD; Niessen HG; Penninx BWJH
Brain Behav Immun; 2021 Oct; 97():167-175. PubMed ID: 34252568
[TBL] [Abstract][Full Text] [Related]
14. Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Sales PMG; Schrage E; Coico R; Pato M
Brain Res; 2023 Feb; 1800():148190. PubMed ID: 36463958
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder.
Yun Y; Zhang Q; Zhao W; Ma T; Fan H; Bai L; Ma B; Qi S; Wang Z; An H; Yang F
J Psychosom Res; 2022 Dec; 163():111069. PubMed ID: 36335711
[TBL] [Abstract][Full Text] [Related]
16. Grey and white matter structure associates with the activation of the tryptophan to kynurenine pathway in bipolar disorder.
Poletti S; Melloni E; Aggio V; Colombo C; Valtorta F; Benedetti F; Comai S
J Affect Disord; 2019 Dec; 259():404-412. PubMed ID: 31610997
[TBL] [Abstract][Full Text] [Related]
17. Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide.
Messaoud A; Mensi R; Douki W; Neffati F; Najjar MF; Gobbi G; Valtorta F; Gaha L; Comai S
World J Biol Psychiatry; 2019 Nov; 20(9):703-711. PubMed ID: 29683396
[No Abstract] [Full Text] [Related]
18. The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Ou W; Chen Y; Ju Y; Ma M; Qin Y; Bi Y; Liao M; Liu B; Liu J; Zhang Y; Li L
J Affect Disord; 2023 Oct; 339():624-632. PubMed ID: 37467793
[TBL] [Abstract][Full Text] [Related]
19. Selective association of cytokine levels and kynurenine/tryptophan ratio with alterations in white matter microstructure in bipolar but not in unipolar depression.
Comai S; Melloni E; Lorenzi C; Bollettini I; Vai B; Zanardi R; Colombo C; Valtorta F; Benedetti F; Poletti S
Eur Neuropsychopharmacol; 2022 Feb; 55():96-109. PubMed ID: 34847455
[TBL] [Abstract][Full Text] [Related]
20. Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia.
Brum M; Nieberler M; Kehrwald C; Knopf K; Brunkhorst-Kanaan N; Etyemez S; Allers KA; Bittner RA; Slattery DA; McNeill RV; Reif A; Kittel-Schneider S
World J Biol Psychiatry; 2023; 24(7):564-577. PubMed ID: 36648064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
